Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen monotherapy versus combined therapies for diabetic retinopathy
2009-009909-25Phase 2Terminated
- Sponsor
- Goethe University Frankfurt
- Start
- Mar 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in diabetic retinopathy (DR) comparing Macugen monotherapy, Macugen plus triamcinolone acetonide and Triamcinolone acetonide monotherapy (3 arms). Primary endpoint: Development of best-corrected visual acuity. Started Mar 2009; status: terminated.
02
Drugs
pegaptanib sodiumtriamcinolone acetonide
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on 2009-009909-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009909-25.